bpc 157 spinal cord injury study Stable gastric pentadecapeptide can improve the healing course of and lead to functional recovery in rats bpc 157 disc herniation study

doi:10.1186/s12916-017-1000-8 Li T, Jiang S, Han M, et al

Briefly, the peptide samples were trapped and washed on Pepmap100 C 18 trap (5m, 0.3 5 mm) at 20ul/min using 2% acetonitrile in water (with 0.1% formic acid) for 10 min and then separated on a Pepman100 RSLC C18 column (2.0 m, 75-m 150-mm) using a gradient of 2%40% acetonitrile with 0.1% formic acid over 120 min at a flow rate of 300 nL/min and a column temperature of 40C

Several factors support the theoretical viability of oral BPC-157, though human outcomes remain unproven: Gastric Stability: BPC-157 was originally studied for gastric protection in animal models, meaning the compound was administered directly into the stomach in research settings

The primary endpoint was AUC 0 for plasma cagrilintide from baseline (day 1) to day 39 (end of study)

PMCID: PMC11806371.

Currently, multiple phase 3 trials with oral semaglutide and orforglipron are ongoing for different populations (NCT05803421), while another oral GLP-1 RA (CT-996) is in early phase clinical trials (Table 1)